Catalyst Wire Dossier Catalyst Wire Dossier

RO-14

ultra-low molecular weight heparin · Rovi Pharmaceuticals Laboratories
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RO-14, covering 2011-06-08 to 2011-06-08. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers [Phase 1]

See pricing